drugset / Trial / NCT01851200
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Phase 2
Completed
9 enrolled
Fondazione Michelangelo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · collabMillennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the activity of Brentuximab vedotin in refractory germ cell tumors.
Timeline
- Start
- 2013-05
- Primary completion
- 2017-08
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |